Objectives of PAPAartis

- To reduce the risk of paraplegia and mortality associated with treatment techniques currently used in patients with thoracoabdominal aortic aneurysms.
- New therapeutic strategy to achieve this goal: Testing a pre-treatment prior to aortic aneurysm repair, potentially preventing spinal cord injury. It is called: MIS²ACE - Minimally invasive staged segmental artery coil embolization.
- Increase individual patient's quality of life.





5 year duration



Recruiting sites in 9 countries

Get In Touch

University of Leipzig Saxonian Incubator for Clinical Translation "SIKT" Philipp-Rosenthal-Straße 55 D-04103 Leipzig Germany

www.papa-artis.eu (use contact sheet on the website)

Twitter: @PAPAartis

This project has received funding from the European Union Horizon 2020 Research and Innovation programme under grant agreement No 733203 and from the German Research Foundation (ET 127/2-1).









Paraplegia Prevention in Aortic Aneurysm Repair by Thoracoabdominal Staging with

Minimally-Invasive Staged Segmental Artery Coil-Embolization

A Randomized Controlled Multicentre Trial


Need for PAPAartis

A thoracoabdominal aortic aneurysm (TAAA) is an enlargement of the aorta which can be fatal if left untreated and allowed to rupture.

Treatment is available and well established, however the most severe complication of the conventional aortic repair techniques is spinal cord injury resulting in paraparesis or paraplegia. Currently this affects 10-20% of patients with TAAA covering a large anatomical region.

How the PAPAartis treatment works

- Minimally invasive staged segmental artery coil embolization (MIS²ACE) as pre-treatment prior to aortic aneurysm repair.
- During MIS²ACE segmental arteries are occluded with coils or plugs.
- MIS²ACE is carried out in up to three sessions (staged process) and triggers blood vessel generation. This then leads to a sufficient blood supply to the spinal cord during aneurysm repair and helps to prevent paraplegia.



PAPAartis Partners



Coordinator: University Leipzig

Recruiting sites

- Silesian Center for Heart Diseases (Zabrze, Poland)
- Medical University of Warsaw (Poland)
- Heart Center Leipzig (Germany)
- University Hospital Leipzig (Germany)
- University Bologna (Italy)
- Ospedale San Raffaele SRL (Milan, Italy)
- Skane University Hospital (Sweden)
- Örebro University Hospital (Sweden)
- Insel Gruppe AG , University Hospital Bern (Switzerland)
- University Hospital Freiburg (Germany)
- Ludwig-Maximilians-University Munich (Germany)
- University Hospital Hamburg (Germany)
- Chu Hopitaux de Bordeaux (France)
- Marie Lannelongue Hospital (France)
- Academisch Ziekenhuis Maastricht (Netherlands)
- St Bartholomews Hospital (England)

PAPAartis Partners

Recruiting sites

- University Hospital Regensburg (Germany)
- University Hospital Nuremberg (Germany)
- Technical University Munich (Germany)
- Hanover Medical School (Germany)
- University Hospital Heidelberg (Germany)
- University Hospital, RWTH Aachen (Germany)
- University Hospital Düsseldorf (Germany)
- University Hospital Münster (Germany)
- German Heart Center Berlin (Germany)
- University Hospital Essen (Germany)
- University Hospital Tübingen (Germany)
- University Hospital Innsbruck (Austria)
- University Hospital Vienna (Austria)

Non-Recruiting partners

- University of Granada (Spain): Health economics
- Region Hovedstaden (Denmark): radiological evaluation, core lab
- European Society of Cardiology (France): Data Safety and Monitoring Board
- European Clinical Research Infrastructure Network (ECRIN; France): national CROs, Monitoring
- Baylor College of Medicine (Texas, USA): Expert Advisors
- University of Pennsylvania (USA): Expert Advisors
- Modus Research and Innovation LTD (Scotland): Dissemination